New cancer drug enters human testing for advanced tumors
NCT ID NCT06457997
Summary
This first-in-human study tested a new cancer drug called PHN-010 in patients with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check the drug's safety, determine the right dose, and see if it could shrink tumors. The trial included 26 patients with specific advanced cancers including lung, colon, ovarian, endometrial, and cervical cancers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AdventHealth
Orlando, Florida, 32804, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
NEXT - San Antonio
San Antonio, Texas, 78229, United States
-
NEXT - Virginia
Fairfax, Virginia, 22031, United States
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
-
University of Washington/Fred Hutchinson Cancer Center
Seattle, Washington, 98109, United States
Conditions
Explore the condition pages connected to this study.